Compare DRTS & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRTS | ETON |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2021 | 2018 |
| Metric | DRTS | ETON |
|---|---|---|
| Price | $13.34 | $47.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $17.80 | ★ $71.50 |
| AVG Volume (30 Days) | ★ 471.5K | 383.4K |
| Earning Date | 11-19-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.41 |
| Revenue | N/A | ★ $79,950,000.00 |
| Revenue This Year | N/A | $87.26 |
| Revenue Next Year | $1,235.59 | $47.21 |
| P/E Ratio | ★ N/A | $123.71 |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $3.43 | $14.27 |
| 52 Week High | $15.79 | $66.37 |
| Indicator | DRTS | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 54.48 | 43.55 |
| Support Level | $13.73 | $48.58 |
| Resistance Level | $15.23 | $57.00 |
| Average True Range (ATR) | 0.66 | 2.33 |
| MACD | 0.10 | 0.16 |
| Stochastic Oscillator | 92.31 | 41.99 |
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.